Development and Validation of a Model for Predicting the Risk of Death in Patients with Acinetobacter baumannii Infection: A Retrospective Study

References

• Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2014;71:292–301. doi:10.1111/2049-632X.1212524376225
   PubMed Web of Science ®Google Scholar
• Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006;42:692–699. doi:10.1086/50020216447117
   PubMed Web of Science ®Google Scholar
• Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018;16:91–102. doi:10.1038/nrmicro.2017.14829249812
   PubMed Web of Science ®Google Scholar
• Ulu-Kilic A, Gundogdu A, Cevahir F, Kilic H, Gunes T, Alp E. An outbreak of bloodstream infection due to extensively resistant Acinetobacter baumannii among neonates. Am J Infect Control. 2018;46:154–158. doi:10.1016/j.ajic.2017.08.00728958447
   PubMed Web of Science ®Google Scholar
• Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198–1208. doi:10.1056/NEJMoa130680124670166
   PubMed Web of Science ®Google Scholar
• Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents. 2016;47:317–323. doi:10.1016/j.ijantimicag.2016.01.01527020541
   PubMed Web of Science ®Google Scholar
• Spellberg B, Rex JH. The value of single-pathogen antibacterial agents. Nat Rev Drug Discov. 2013;12:963. doi:10.1038/nrd3957-c124232373
   PubMed Web of Science ®Google Scholar
• Birgani MT, Ansari H. Antibiotic Characterization of Acinetobacter baumannii isolated from clinical samples and production of recombinant OmpA from resistant strains. Jundishapur J Microbiol. 2018;11:e78773.
   Web of Science ®Google Scholar
• Gu Z, Han Y, Meng T, et al. Risk factors and clinical outcomes for patients with Acinetobacter baumannii bacteremia. Medicine (Baltimore). 2016;95:e2943. doi:10.1097/MD.000000000000294326945403
   PubMed Web of Science ®Google Scholar
• Nazer LH, Kharabsheh A, Rimawi D, Mubarak S, Hawari F. Characteristics and outcomes of Acinetobacter baumannii infections in critically ill patients with cancer: a matched case-control study. Microb Drug Resist. 2015;21:556–561. doi:10.1089/mdr.2015.003226430944
   PubMed Web of Science ®Google Scholar
• Shargian-Alon L, Gafter-Gvili A, Ben-Zvi H, et al. Risk factors for mortality due to Acinetobacter baumannii bacteremia in patients with hematological malignancies - a retrospective study. Leuk Lymphoma. 2019;60:2787–2792. doi:10.1080/10428194.2019.159911331014145
   PubMed Web of Science ®Google Scholar
• Ciginskiene A, Dambrauskiene A, Rello J, Adukauskiene D. Ventilator-associated pneumonia due to drug-resistant Acinetobacter baumannii: risk factors and mortality relation with resistance profiles, and independent predictors of in-hospital mortality. Medicina (Kaunas). 2019;55:49.
   Web of Science ®Google Scholar
• Jang TN, Lee SH, Huang CH, Lee CL, Chen WY. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study. J Hosp Infect. 2009;73:143–150. doi:10.1016/j.jhin.2009.06.00719716203
   PubMed Web of Science ®Google Scholar
• Russo A, Bassetti M, Ceccarelli G, et al. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study. J Infect. 2019;79:130–138. doi:10.1016/j.jinf.2019.05.01731145911
   PubMed Web of Science ®Google Scholar
• Oh DH, Kim YC, Kim EJ, et al. Multidrug-resistant Acinetobacter baumannii infection in lung transplant recipients: risk factors and prognosis. Infect Dis (Lond). 2019;51:493–501. doi:10.1080/23744235.2018.155640031081415
   PubMed Web of Science ®Google Scholar
• Martin-Aspas A, Guerrero-Sanchez FM, Garcia-Colchero F, Rodriguez-Roca S, Giron-Gonzalez JA. Differential characteristics of Acinetobacter baumannii colonization and infection: risk factors, clinical picture, and mortality. Infect Drug Resist. 2018;11:861–872. doi:10.2147/IDR.S16394429922077
   PubMed Web of Science ®Google Scholar
• Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Br J Surg. 2015;102:148–158. doi:10.1002/bjs.973625627261
   PubMed Web of Science ®Google Scholar
• Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309–332. doi:10.1016/j.ajic.2008.03.00218538699
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. doi:10.1016/0021-9681(87)90171-83558716
   PubMedGoogle Scholar
• Harrell FE Jr., Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247:2543–2546. doi:10.1001/jama.1982.033204300470307069920
   PubMed Web of Science ®Google Scholar
• Niu XK, He WF, Zhang Y, et al. Developing a new PI-RADS v2-based nomogram for forecasting high-grade prostate cancer. Clin Radiol. 2017;72:458–464. doi:10.1016/j.crad.2016.12.00528069159
   PubMed Web of Science ®Google Scholar
• Holmberg L, Vickers A. Evaluation of prediction models for decision-making: beyond calibration and discrimination. PLoS Med. 2013;10:e1001491. doi:10.1371/journal.pmed.100149123935462
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26:565–574. doi:10.1177/0272989X0629536117099194
   PubMed Web of Science ®Google Scholar
• Villar M, Cano ME, Gato E, et al. Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: a reappraisal. Medicine (Baltimore). 2014;93:202–210. doi:10.1097/MD.000000000000003625181313
   PubMed Web of Science ®Google Scholar
• Lopez-Cortes LE, Cisneros JM, Fernandez-Cuenca F, et al. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother. 2014;69:3119–3126. doi:10.1093/jac/dku23324970742
   PubMed Web of Science ®Google Scholar
• Livermore DM, Hill RL, Thomson H, et al. Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London. Int J Antimicrob Agents. 2010;35:19–24. doi:10.1016/j.ijantimicag.2009.09.01419910162
   PubMed Web of Science ®Google Scholar
• Lemos EV, de la Hoz FP, Einarson TR, et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect. 2014;20:416–423. doi:10.1111/1469-0691.1236324131374
   PubMed Web of Science ®Google Scholar
• Brotfain E, Borer A, Koyfman L, et al. Multidrug resistance Acinetobacter bacteremia secondary to ventilator-associated pneumonia: risk factors and outcome. J Intensive Care Med. 2017;32:528–534. doi:10.1177/088506661663219326902255
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317. doi:10.1086/42194615306996
   PubMed Web of Science ®Google Scholar
• Nutman A, Glick R, Temkin E, et al. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia. Clin Microbiol Infect. 2014;20:O1028–1034. doi:10.1111/1469-0691.1271624930471
   PubMed Web of Science ®Google Scholar
• Ballouz T, Aridi J, Afif C, et al. Risk factors, clinical presentation, and outcome of Acinetobacter baumannii Bacteremia. Front Cell Infect Microbiol. 2017;7:156. doi:10.3389/fcimb.2017.0015628523249
   PubMed Web of Science ®Google Scholar
• Freire MP, de Oliveira Garcia D, Garcia CP, et al. Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. Clin Microbiol Infect. 2016;22:352–358. doi:10.1016/j.cmi.2015.12.01026711434
   PubMed Web of Science ®Google Scholar
• Levy MM, Artigas A, Phillips GS, et al. Outcomes of the surviving sepsis campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis. 2012;12:919–924. doi:10.1016/S1473-3099(12)70239-623103175
   PubMed Web of Science ®Google Scholar
• Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis. 2009;9:245–255. doi:10.1016/S1473-3099(09)70055-619324297
   PubMed Web of Science ®Google Scholar
• Xiao J, Zhang C, Ye S. Acinetobacter baumannii meningitis in children: a case series and literature review. Infection. 2019;47:643–649. doi:10.1007/s15010-018-1234-130328074
   PubMed Web of Science ®Google Scholar
• Cascio A, Conti A, Sinardi L, et al. Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int J Infect Dis. 2010;14:e572–579. doi:10.1016/j.ijid.2009.06.03219892577
   PubMed Web of Science ®Google Scholar
• Shirazi AS, Shafiei M, Solgi H, Aslani MM, Azizi O, Badmasti F. Different virulence capabilities and ompA expressions in ST2 and ST513 of multidrug-resistant Acinetobacter baumannii.. Curr Microbiol. 2019;76:723–731. doi:10.1007/s00284-019-01686-930989324
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Available from: http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. Accessed 1111, 2018.
   Google Scholar
• Hu F, Guo Y, Yang Y, et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis 2019;38(12):2275–2281.
   Google Scholar
• Wang X, Zhang L, Sun A, et al. Acinetobacter baumannii bacteraemia in patients with haematological malignancy: a multicentre retrospective study from the Infection Working Party of Jiangsu Society of Hematology. Eur J Clin Microbiol Infect Dis. 2017;36:1073–1081. doi:10.1007/s10096-016-2895-228101785
   PubMed Web of Science ®Google Scholar
• Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis. 2005;11:22–29. doi:10.3201/eid1101.04000115705318
   PubMed Web of Science ®Google Scholar
• Arvaniti K, Lathyris D, Ruimy R, et al. The importance of colonization pressure in multiresistant Acinetobacter baumannii acquisition in a Greek intensive care unit. Crit Care. 2012;16:R102. doi:10.1186/cc1138322694969
   PubMed Web of Science ®Google Scholar
• Erbay A, Idil A, Gozel MG, Mumcuoglu I, Balaban N. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents. 2009;34:575–579. doi:10.1016/j.ijantimicag.2009.07.00619740628
   PubMed Web of Science ®Google Scholar
• de Gouvea EF, Martins IS, Halpern M, et al. The influence of carbapenem resistance on mortality in solid organ transplant recipients with Acinetobacter baumannii infection. BMC Infect Dis. 2012;12:351. doi:10.1186/1471-2334-12-35123237530
   PubMed Web of Science ®Google Scholar
• Yang S, Sun J, Wu X, Zhang L. Determinants of mortality in patients with Nosocomial Acinetobacter baumannii Bacteremia in Southwest China: a five-year case-control study. Can J Infect Dis Med Microbiol. 2018;2018:3150965. doi:10.1155/2018/315096529973964
   PubMed Web of Science ®Google Scholar
• Ushizawa H, Yahata Y, Endo T, et al. A Epidemiological Investigation of a Nosocomial Outbreak of Multidrug-Resistant Acinetobacter baumannii in a Critical Care Center in Japan, 2011–2012. Jpn J Infect Dis. 2016;69:356. doi:10.7883/yoken.JJID.2016.E00227452226
   PubMed Web of Science ®Google Scholar
• Van Hemelrijck M, Harari D, Garmo H, et al. Biomarker-based score to predict mortality in persons aged 50 years and older: a new approach in the Swedish AMORIS study. Int J Mol Epidemiol Genet. 2012;3:66–76.22493753
   PubMedGoogle Scholar